Thrombosis and Haemostasis, Inhaltsverzeichnis Thromb Haemost 2005; 93(01): 70-75DOI: 10.1160/TH04-06-0394 Blood Coagulation, Fibrinolysis and Cellular Haemostasis Schattauer GmbH Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera Autor*innen Institutsangaben Mathias Kees 1 Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University Vienna, Vienna, Austria Franz Wiesbauer 2 Department of Internal Medicine II, Division of Cardiology, Medical University Vienna, Vienna, Austria Bettina Gisslinger 1 Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University Vienna, Vienna, Austria Renate Wagner 1 Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University Vienna, Vienna, Austria Medhat Shehata 1 Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University Vienna, Vienna, Austria Heinz Gisslinger 1 Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University Vienna, Vienna, Austria Artikel empfehlen Abstract Volltext als PDF herunterladen(opens in new window) Keywords KeywordsOsteoprotegerin - polycythemia vera - thrombosis - bleeding - vascular complications Referenzen References 1 Gruppo Italiano Studio Policitemia Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-64. 2 Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100: 4272-90. 3 Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978; 2: 1219-22. 4 Ruggeri M, Gisslinger H, Tosetto A. et al Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002; 71: 1-6. 5 Gisslinger H, Rodeghiero F, Ruggeri M. et al Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Br J Haematol 1999; 105: 551-5. 6 Michiels JJ. Erythromelalgia and thrombocythemia: a disease of platelet prostaglandin metabolism. Semin Thromb Hemost 1997; 23: 335-8. 7 Neunteufl T, Heher S, Stefenelli T. et al Endothelial dysfunction in patients with polycythaemia vera. Br J Haematol 2001; 115: 354-9. 8 Falanga A, Marchetti M, Evangelista V. et al Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261-6. 9 Cines DB, Pollak ES, Buck CA. et al Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61. 10 Jono S, Ikari Y, Shioi A. et al Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-4. 11 Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-7. 12 Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22: 549-53. 13 Simonet WS, Lacey DL, Dunstan CR. et al Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19. 14 Lacey DL, Timms E, Tan HL. et al Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76. 15 Fata JE, Kong YY, Li J. et al The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000; 103: 41-50. 16 Bucay N, Sarosi I, Dunstan CR. et al osteoprotegerin- deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-8. 17 Kim HH, Shin HS, Kwak HJ. et al RANKL regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. FASEB J 2003; 17: 2163-5. 18 Collin-Osdoby P, Rothe L, Anderson F. et al Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001; 276: 20659-72. 19 Zhang J, Fu M, Myles D et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002; 521: 180-4. 20 Tan KB, Harrop J, Reddy M. et al Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 1997; 204: 35-46. 21 Schoppet M, Sattler AM, Schaefer JR. et al Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024-8. 22 Knudsen ST, Foss CH, Poulsen PL. et al Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003; 149: 39-42. 23 Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombo-cythemia. Semin Hematol 1999; 36: 9-13. 24 Landolfi R, Marchioli R, Kutti J. et al Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-24. 25 Rothman K, Greenland S. Modern Epidemiology Philadelphia: Lippincott Williams & Wilkins; 1998: 255-7. 26 Clayton D, Hills M. Statistical Models in Epidemiology. Oxford: Oxford University Press; 1993 27 Chagraoui H, Tulliez M, Smayra T. et al Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood 2003; 101: 2983-9. 28 Chagraoui H, Sabri S, Capron C. et al Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. Exp Hematol 2003; 31: 1081-8. 29 Malyankar UM, Scatena M, Suchland KL. et al Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000; 275: 20959-62.
